Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
BTTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.21
N/A
-0.71
vs NA
Q1.22
N/A
-0.41
vs -0.23
Q2.22
N/A
-0.42
vs -0.37
Q3.22
N/A
-0.48
vs -0.03
Q4.22
N/A
-0.71
vs -0.71
Q1.23
N/A
-0.37
vs -0.41
Q2.23
N/A
-0.24
vs -0.42
Q3.23
N/A
-0.15
vs -0.48
Q4.23
N/A
-0.12
vs -0.71
Q1.24
N/A
-0.17
vs -0.37
Sales Growth
YoY
Current
Estimates
Q2.21
-100%
NA vs 3K
Q3.21
NA
NA vs NA
Q4.21
+27260%
284K vs 1K
Q1.22
NA
NA vs NA
Q2.22
NA
NA vs NA
Q3.22
NA
NA vs NA
Q4.22
-100%
NA vs 284K
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Return on Equity
QoQ
Q4.21
-38%
-0.38
vs -0.00
Q1.22
-36%
-0.36
vs -0.38
Q2.22
-55%
-0.55
vs -0.36
Q3.22
-157%
-1.57
vs -0.55
Q4.22
+975%
9.75
vs -1.57
Q1.23
+95%
0.95
vs 9.75
Q2.23
+70%
0.7
vs 0.95
Q3.23
+59%
0.59
vs 0.7
Institutionnal Ownership
QoQ
Q4.22
21
21
vs 16
31%
Q1.23
18
18
vs 21
-14%
Q2.23
13
13
vs 18
-28%
Q3.23
18
18
vs 13
38%
Q4.23
22
22
vs 18
22%
Q1.24
3
3
vs 22
-86%
Q2.24
1
1
vs 3
-67%
Q1.25
1
1
vs NA
NA
businesswire.com
9 hours ago
zacks.com
11 hours ago
Quote Panel
Key Metrics
Relative Strength
BTTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
NaN%2024-Revenue
-567%2024-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
Wells Fargo
upgradePrevious: Not converted
2022-05-03
Now: Equal-Weight
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
OTC
Unprofitable
EPS improving
Unprofitable
EPS improving
Pre-market 0.00$0.00 (0.00%)
Relative Strenght
11
Volume Buzz
-99%
Earning Acce
Yes
Dist 52w H.
100%